The complete response letter (CRL) that ACADIA Pharmaceuticals Inc. got from the US Food and Drug Administration for Nuplazid (pimavanserin) in Alzheimer’s disease psychosis (ADP) did not come as a surprise, given the negative FDA advisory committee vote for the drug in June. But it’s still a significant setback for the company, and it remains uncertain whether it will continue pursuing the indication in another trial.
Future Of Acadia’s Nuplazid In Alzheimer’s Psychosis Unclear After CRL
An analyst had suggested that in the event of a thumbs-down from the FDA, the company could end up focusing on other catalysts instead.
